CN102316892B - 心肌营养素-1用于治疗代谢病的用途 - Google Patents
心肌营养素-1用于治疗代谢病的用途 Download PDFInfo
- Publication number
- CN102316892B CN102316892B CN201080009256.9A CN201080009256A CN102316892B CN 102316892 B CN102316892 B CN 102316892B CN 201080009256 A CN201080009256 A CN 201080009256A CN 102316892 B CN102316892 B CN 102316892B
- Authority
- CN
- China
- Prior art keywords
- insulin
- treatment
- rct
- mice
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Description
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200900396 | 2009-02-12 | ||
ES200900396 | 2009-02-12 | ||
PCT/ES2010/070072 WO2010092218A2 (es) | 2009-02-12 | 2010-02-10 | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102316892A CN102316892A (zh) | 2012-01-11 |
CN102316892B true CN102316892B (zh) | 2014-06-04 |
Family
ID=42562119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080009256.9A Expired - Fee Related CN102316892B (zh) | 2009-02-12 | 2010-02-10 | 心肌营养素-1用于治疗代谢病的用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110293562A1 (zh) |
EP (1) | EP2397152B1 (zh) |
JP (1) | JP2012517459A (zh) |
CN (1) | CN102316892B (zh) |
AU (1) | AU2010212794A1 (zh) |
BR (1) | BRPI1008415A2 (zh) |
CA (1) | CA2750074A1 (zh) |
ES (1) | ES2493618T3 (zh) |
MX (1) | MX2011008562A (zh) |
RU (1) | RU2011137413A (zh) |
WO (1) | WO2010092218A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11419916B2 (en) | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
JP2017507670A (ja) * | 2014-02-24 | 2017-03-23 | エナジーシス ファーマシューティカルズ, インコーポレイテッド | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
EP0179904A1 (en) | 1984-05-09 | 1986-05-07 | Medaphore Inc. | Oral insulin and a method of making the same |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4992417A (en) | 1987-07-17 | 1991-02-12 | Mount Sinai School Of Medicine | Superactive human insulin analogues |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
AR002976A1 (es) | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
PE79099A1 (es) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
PL193111B1 (pl) | 1998-01-29 | 2007-01-31 | Poly Med Inc | Związana mikrocząstka, otoczona mikrocząstka zawierająca co najmniej jedną związaną mikrocząstkę, kompozycja farmaceutyczna zawierająca związaną mikrocząstkę lub otoczoną mikrocząstkę oraz sposób wytwarzania otoczonej mikrocząstki |
EP1932535A3 (en) | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
US20040110287A1 (en) * | 2002-07-29 | 2004-06-10 | Es Cell International Pte Ltd. | Multi-step method for the differentiation of insulin positive, glucose responsive cells |
WO2005053728A2 (de) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik |
GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
EP1863841A1 (en) * | 2005-03-17 | 2007-12-12 | Novo Nordisk A/S | Compounds for use in the treatment of obesity |
WO2007093363A1 (en) | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
-
2010
- 2010-02-10 US US13/201,431 patent/US20110293562A1/en not_active Abandoned
- 2010-02-10 WO PCT/ES2010/070072 patent/WO2010092218A2/es active Application Filing
- 2010-02-10 CA CA2750074A patent/CA2750074A1/en not_active Abandoned
- 2010-02-10 ES ES10710061.2T patent/ES2493618T3/es active Active
- 2010-02-10 AU AU2010212794A patent/AU2010212794A1/en not_active Abandoned
- 2010-02-10 CN CN201080009256.9A patent/CN102316892B/zh not_active Expired - Fee Related
- 2010-02-10 RU RU2011137413/15A patent/RU2011137413A/ru unknown
- 2010-02-10 JP JP2011549615A patent/JP2012517459A/ja active Pending
- 2010-02-10 BR BRPI1008415-0A patent/BRPI1008415A2/pt not_active IP Right Cessation
- 2010-02-10 EP EP10710061.2A patent/EP2397152B1/en active Active
- 2010-02-10 MX MX2011008562A patent/MX2011008562A/es not_active Application Discontinuation
Non-Patent Citations (6)
Title |
---|
"Effects of Cardiotrophin on Adipocytes";Sanjin Zvonic et al.,;《The Journal of Biological Chemistry》;20040831;第279卷(第46期);第47572页-第47579页 * |
"gp130 receptor ligands as potential therapeutic targets for obesity";Mark A.Febbraio;《Journal of Clinical Investigation》;20070402;第117卷(第4期);第841页-第849页 * |
B.Macros-Gomez et al.,."Obesity, inflammation and insulin resistance:role of gp 130 receptor ligands".《An Sist Sanit Navar》.2008,第31卷(第2期),第113页-第123页. |
B.Macros-Gomez et al.,."Obesity, inflammation and insulin resistance:role of gp 130 receptor ligands".《An Sist Sanit Navar》.2008,第31卷(第2期),第113页-第123页. * |
Mark A.Febbraio."gp130 receptor ligands as potential therapeutic targets for obesity".《Journal of Clinical Investigation》.2007,第117卷(第4期),第841页-第849页. |
Sanjin Zvonic et al.,."Effects of Cardiotrophin on Adipocytes".《The Journal of Biological Chemistry》.2004,第279卷(第46期),第47572页-第47579页. |
Also Published As
Publication number | Publication date |
---|---|
AU2010212794A1 (en) | 2011-08-11 |
BRPI1008415A2 (pt) | 2018-02-27 |
EP2397152B1 (en) | 2014-05-28 |
JP2012517459A (ja) | 2012-08-02 |
WO2010092218A3 (es) | 2010-11-18 |
CN102316892A (zh) | 2012-01-11 |
ES2493618T3 (es) | 2014-09-12 |
MX2011008562A (es) | 2011-09-09 |
RU2011137413A (ru) | 2013-03-20 |
EP2397152A2 (en) | 2011-12-21 |
US20110293562A1 (en) | 2011-12-01 |
WO2010092218A2 (es) | 2010-08-19 |
CA2750074A1 (en) | 2010-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tonelli et al. | Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes | |
Dakin et al. | Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats | |
CN103491975B (zh) | 酰化胰高血糖素类似物与胰岛素类似物的组合 | |
EA026712B1 (ru) | Применение ингибитора sglt2 | |
WO2007112069A2 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
CN110628723B (zh) | 基因修饰MSCs治疗2型糖尿病 | |
CN102316892B (zh) | 心肌营养素-1用于治疗代谢病的用途 | |
CN104039357A (zh) | 胰腺β-细胞增殖的调节 | |
CN102389413A (zh) | 用于治疗糖尿病的组合物及其应用 | |
Dreyer et al. | Leptin activates the promoter of the interleukin-1 receptor antagonist through P42/44 mitogen-activated protein kinase and a composite nuclear factor kappaB/PU. 1 binding site | |
Palin et al. | The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFα-induced sickness behavior | |
Padrutt et al. | Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats | |
ES2818556T3 (es) | Péptido con eficacia antiobesidad y antidiabética y uso del mismo | |
Prasathkumar et al. | Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: an insight on molecular approaches | |
Haas et al. | Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats | |
CN112891540A (zh) | Ogt作为靶点在制备治疗糖尿病中胰高血糖素异常分泌的药物中的应用 | |
Glass et al. | Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala dynorphin gene expression | |
KR20200067745A (ko) | Fas 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물 | |
EP3800196A1 (en) | Peptide for treating rheumatoid arthritis and use thereof | |
CN111991408B (zh) | 槲皮素-3-o-刺槐糖苷作为钙离子通道的抑制剂的应用 | |
CN114129711A (zh) | 度拉糖肽在制备抗肿瘤药物中的应用 | |
CN108795984A (zh) | 一种利用腺病毒载体构建小肠降表达胰岛素大鼠模型的方法 | |
KR102389898B1 (ko) | Fgf11 발현을 억제하는 제제를 포함하는 대사질환 예방 또는 치료용 조성물 | |
CN109966494A (zh) | 一种预防和/或治疗糖尿病的药物及vegfr1抑制剂在该药物中的应用 | |
WO2022061962A1 (zh) | 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: UNIVERSIDAD DE NAVARRA Free format text: FORMER OWNER: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA S A Effective date: 20130320 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130320 Address after: Navarra Spain Applicant after: Proyecto Biomedicina Cima Sl Applicant after: UNIV DE NAVARRA Address before: Navarra Spain Applicant before: Proyecto Biomedicina Cima Sl Applicant before: Instituto Cientifico Y Tecnologico De Navarra S A |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140604 Termination date: 20150210 |
|
EXPY | Termination of patent right or utility model |